Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.56 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 10/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601405 | 0.88 | KDM4E (0.52) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20601472 | 0.88 | KDM4E (0.56) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20601295 | 0.87 | KDM4E (0.58) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20601297 | 0.87 | KDM4E (0.58) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20601244 | 0.87 | KDM4E (0.51) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20601301 | 0.87 | KDM4E (0.53) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20618746 | 0.86 | KDM4E (0.54) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20601245 | 0.85 | CCR1 (0.49) | ITGB3ITGA2BKDM4EGAACCR1 | |
| SCHEMBL20618552 | 0.85 | KDM4E (0.58) | ITGB3ITGA2BKDM4EGAAUTS2R | |
| SCHEMBL23111244 | 0.85 | KDM4E (0.51) | ITGB3ITGA2BKDM4EGAACCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-03-18 | — | — | US | disclosed |
| EP-3645519-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019003142-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078988-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | ITGB3 4503/4885ITGA2B 4280/4885KDM4E 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.